Ani Pharmaceuticals (ANIP) Other Accumulated Expenses (2010 - 2026)

Ani Pharmaceuticals has reported Other Accumulated Expenses for 17 years, with the latest figure at $33.9 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 43.07% year-over-year to $33.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.9 million (up 43.07% YoY) and the FY2025 annual result came in at $48.5 million, up 114.34% from the prior year.
• Other Accumulated Expenses declined to $33.9 million in Q1 2026 per ANIP's latest filing, from $48.5 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $51.2 million in Q3 2025 and troughed at $5.0 million in Q1 2022.
• A 5-year average of $20.6 million and a median of $16.3 million in 2023 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses dropped 5.88% in 2022, then soared 118.57% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $9.3 million in 2022, then surged by 74.88% to $16.3 million in 2023, then jumped by 39.01% to $22.6 million in 2024, then surged by 114.34% to $48.5 million in 2025, then slumped by 30.05% to $33.9 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $33.9 million, $48.5 million, and $51.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.